Search companies

Live

Tuesday, 17 November 2026 · 583 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Neuren Wins FDA Orphan Drug Designation for Brain Injury Treatment Candidate

NEU: $20.75 +1.92% · MC: $2.9B

The FDA has granted orphan drug designation to Neuren Pharmaceuticals’ NNZ-2591 for neonatal hypoxic-ischemic encephalopathy, a brain injury caused by insufficient oxygen or blood flow around birth. Neuren is conducting an animal safety study required before a clinical trial and plans to submit an application to begin clinical testing in the first half of 2027. The designation provides incentives including potential marketing exclusivity if the drug is approved.

Source announcements: 2026-11-02 10:37 to 2026-11-02 10:37 Sydney time
Story updated 2026-11-02 11:25 Sydney time
SourcesFDA grants Orphan Drug Designation for NNZ-2591 to treat HIE
Comments